Clinical Trials Directory

Trials / Completed

CompletedNCT01219920

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
244 (actual)
Sponsor
Gruppo Oncologico del Nord-Ovest · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of response rate to conventional chemotherapy with the FOLFIRI regimen as first-line treatment of metastatic colorectal cancer patients.

Detailed description

Survival of patients with metastatic colorectal cancer is correlated with the proportion of patients who receive all the three active drugs in the course of the disease, but not with the proportion of patients who receive any second-line therapy. In a sequential strategy, not all patients who progress after first-line chemotherapy are able to receive second-line treatment. Moreover, there is a correlation between the response rate to chemotherapy and the postchemotherapy radical resection rate of metastases. Therefore, a way to improve the outcome of metastatic colorectal cancer patients could be to administer a first-line regimen containing the three active agents.

Conditions

Interventions

TypeNameDescription
DRUGFOLFIRIIrinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
DRUGFOLFOXIRIIrinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks

Timeline

Start date
2001-11-01
Primary completion
2005-11-01
Completion
2009-11-01
First posted
2010-10-13
Last updated
2015-03-11

Locations

48 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT01219920. Inclusion in this directory is not an endorsement.